New York (N.Y.) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortman as Cellectis' Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman, who will be based in Cellectis'New York office, is also joining the Company's executive committee.
"Ky is an accomplished human resources leader who brings over 25 years of experience in the biotech/biopharma industries to Cellectis. She will lead Cellectis' human resources strategies and contribute to the Company's overarching mission, which will ultimately help drive our business toward commercialization," said Dr. Andre Choulika, Chief Executive Officer, Cellectis. "Furthermore, Ky has worked globally with some of the most successful biopharma companies and has an extensive background specializing in multiple areas of human resources. Her vast experience working with biotech leaders across the board to maximize human capital will make her an invaluable asset to our growing team."
In her new role at Cellectis, Ms. Nam-Wortman will work closely with Dr. Choulika and the executive management team to ensure that the Company advances its roadmap through the recruitment and retention of top talent. She will also work to further develop and enhance Cellectis' dynamic and inclusive culture, while optimizing the Company's human resources function.
Kyung Nam-Wortman joins Cellectis from Achillion (recently acquired by Alexion in January 2020) where she served as Senior Vice President, Head of Human Resources, Head of Information Technology, Facilities and Internal Communications. At Achillion, she was responsible for leading the strategic and operational components of the aforementioned functions.
Prior to her tenure at Achillion, Ms. Nam-Wortman served as Vice President and Head of Global Talent and Organization Capability at Zoetis, where she supported the spin-off of Pfizer's animal health business unit through its IPO and was responsible for the stand up of Zoetis' global talent management function to support the company's growth worldwide. She also held various human resource leadership roles for Pfizer's business units, divisions, and functions with regional and global accountabilities.
In addition to her experience in biotech/biopharma, Ms. Nam-Wortman has 14 years of experience in the consulting industry focused on strategic and organization change management from Delta Consulting Group and IBM. She received her bachelor's in marketing from New York University Stern School of Business and MS in human resources management / organization development from the New School of Social Research.
"From Day One, Cellectis' commitment to developing a cure for cancer patients in need utilizing its novel gene-editing technology has resonated deeply with me. I look forward to working with the team to help shape the future of the Company," said Ms. Nam-Wortman. "The success of any company ultimately starts with its people and culture. Continuing to find and develop the right talent for such a purpose-driven organization will be of the utmost importance for me, and ultimately, for Cellectis moving forward." Download the PDF file
(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE